Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative
Background: The Gut and Obesity Asia (GO ASIA) workgroup was formed to study the relationships between obesity and gastrointestinal diseases in the Asia Pacific region. Aim: To study factors associated with nonalcoholic steatohepatitis (NASH) and advanced fibrosis, and medical treatment of biopsy-pr...
| Hlavní autoři: | , , , , , , , , , , , , , , |
|---|---|
| Médium: | Článek |
| Vydáno: |
Wiley
2018
|
| Témata: |
| _version_ | 1825721840252747776 |
|---|---|
| author | Chan, Wah Kheong Treeprasertsuk, Sombat Imajo, Kento Nakajima, Atsushi Seki, Yousuke Kasama, Kazunori Kakizaki, Satoru Fan, Jian Gao Song, Myeong Jun Yoon, Seung Kew Dan, Yock Young Lesmana, Laurentius Ho, Khek Yu Goh, Khean Lee Wong, Vincent Wai Sun |
| author_facet | Chan, Wah Kheong Treeprasertsuk, Sombat Imajo, Kento Nakajima, Atsushi Seki, Yousuke Kasama, Kazunori Kakizaki, Satoru Fan, Jian Gao Song, Myeong Jun Yoon, Seung Kew Dan, Yock Young Lesmana, Laurentius Ho, Khek Yu Goh, Khean Lee Wong, Vincent Wai Sun |
| author_sort | Chan, Wah Kheong |
| collection | UM |
| description | Background: The Gut and Obesity Asia (GO ASIA) workgroup was formed to study the relationships between obesity and gastrointestinal diseases in the Asia Pacific region. Aim: To study factors associated with nonalcoholic steatohepatitis (NASH) and advanced fibrosis, and medical treatment of biopsy-proven nonalcoholic fatty liver disease (NAFLD) patients. Methods: Retrospective study of biopsy-proven NAFLD patients from centres in the GO ASIA Workgroup. Independent factors associated with NASH and with advanced fibrosis on binary logistic regression analyses in a training cohort were used for the development of their corresponding risk score, which were validated in a validation cohort. Results: We included 1008 patients from nine centres across eight countries (NASH 62.9%, advanced fibrosis 17.2%). Independent predictors of NASH were body mass index ≥30 kg/m2, diabetes mellitus, dyslipidaemia, alanine aminotransferase ≥88 U/L and aspartate aminotransferase ≥38 U/L, constituting the Asia Pacific NASH risk score. A high score has a positive predictive value of 80%-83% for NASH. Independent predictors of advanced fibrosis were age ≥55 years, diabetes mellitus and platelet count <150 × 109/L, constituting the Asia-Pacific NAFLD advanced fibrosis risk score. A low score has a negative predictive value of 95%-96% for advanced fibrosis. Only 1.7% of patients were referred for structured lifestyle program, 4.2% were on vitamin E, and 2.4% were on pioglitazone. Conclusions: More severe liver disease can be suspected or ruled out based on factors identified in this study. Utilisation of structured lifestyle program, vitamin E and pioglitazone was limited despite this being a cohort of biopsy-proven NAFLD patients with majority of patients having NASH. |
| first_indexed | 2024-03-06T05:56:29Z |
| format | Article |
| id | um.eprints-22274 |
| institution | Universiti Malaya |
| last_indexed | 2024-03-06T05:56:29Z |
| publishDate | 2018 |
| publisher | Wiley |
| record_format | dspace |
| spelling | um.eprints-222742019-09-06T04:18:27Z http://eprints.um.edu.my/22274/ Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative Chan, Wah Kheong Treeprasertsuk, Sombat Imajo, Kento Nakajima, Atsushi Seki, Yousuke Kasama, Kazunori Kakizaki, Satoru Fan, Jian Gao Song, Myeong Jun Yoon, Seung Kew Dan, Yock Young Lesmana, Laurentius Ho, Khek Yu Goh, Khean Lee Wong, Vincent Wai Sun R Medicine Background: The Gut and Obesity Asia (GO ASIA) workgroup was formed to study the relationships between obesity and gastrointestinal diseases in the Asia Pacific region. Aim: To study factors associated with nonalcoholic steatohepatitis (NASH) and advanced fibrosis, and medical treatment of biopsy-proven nonalcoholic fatty liver disease (NAFLD) patients. Methods: Retrospective study of biopsy-proven NAFLD patients from centres in the GO ASIA Workgroup. Independent factors associated with NASH and with advanced fibrosis on binary logistic regression analyses in a training cohort were used for the development of their corresponding risk score, which were validated in a validation cohort. Results: We included 1008 patients from nine centres across eight countries (NASH 62.9%, advanced fibrosis 17.2%). Independent predictors of NASH were body mass index ≥30 kg/m2, diabetes mellitus, dyslipidaemia, alanine aminotransferase ≥88 U/L and aspartate aminotransferase ≥38 U/L, constituting the Asia Pacific NASH risk score. A high score has a positive predictive value of 80%-83% for NASH. Independent predictors of advanced fibrosis were age ≥55 years, diabetes mellitus and platelet count <150 × 109/L, constituting the Asia-Pacific NAFLD advanced fibrosis risk score. A low score has a negative predictive value of 95%-96% for advanced fibrosis. Only 1.7% of patients were referred for structured lifestyle program, 4.2% were on vitamin E, and 2.4% were on pioglitazone. Conclusions: More severe liver disease can be suspected or ruled out based on factors identified in this study. Utilisation of structured lifestyle program, vitamin E and pioglitazone was limited despite this being a cohort of biopsy-proven NAFLD patients with majority of patients having NASH. Wiley 2018 Article PeerReviewed Chan, Wah Kheong and Treeprasertsuk, Sombat and Imajo, Kento and Nakajima, Atsushi and Seki, Yousuke and Kasama, Kazunori and Kakizaki, Satoru and Fan, Jian Gao and Song, Myeong Jun and Yoon, Seung Kew and Dan, Yock Young and Lesmana, Laurentius and Ho, Khek Yu and Goh, Khean Lee and Wong, Vincent Wai Sun (2018) Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative. Alimentary Pharmacology & Therapeutics, 47 (6). pp. 816-825. ISSN 0269-2813, DOI https://doi.org/10.1111/apt.14506 <https://doi.org/10.1111/apt.14506>. https://doi.org/10.1111/apt.14506 doi:10.1111/apt.14506 |
| spellingShingle | R Medicine Chan, Wah Kheong Treeprasertsuk, Sombat Imajo, Kento Nakajima, Atsushi Seki, Yousuke Kasama, Kazunori Kakizaki, Satoru Fan, Jian Gao Song, Myeong Jun Yoon, Seung Kew Dan, Yock Young Lesmana, Laurentius Ho, Khek Yu Goh, Khean Lee Wong, Vincent Wai Sun Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative |
| title | Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative |
| title_full | Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative |
| title_fullStr | Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative |
| title_full_unstemmed | Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative |
| title_short | Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative |
| title_sort | clinical features and treatment of nonalcoholic fatty liver disease across the asia pacific region the go asia initiative |
| topic | R Medicine |
| work_keys_str_mv | AT chanwahkheong clinicalfeaturesandtreatmentofnonalcoholicfattyliverdiseaseacrosstheasiapacificregionthegoasiainitiative AT treeprasertsuksombat clinicalfeaturesandtreatmentofnonalcoholicfattyliverdiseaseacrosstheasiapacificregionthegoasiainitiative AT imajokento clinicalfeaturesandtreatmentofnonalcoholicfattyliverdiseaseacrosstheasiapacificregionthegoasiainitiative AT nakajimaatsushi clinicalfeaturesandtreatmentofnonalcoholicfattyliverdiseaseacrosstheasiapacificregionthegoasiainitiative AT sekiyousuke clinicalfeaturesandtreatmentofnonalcoholicfattyliverdiseaseacrosstheasiapacificregionthegoasiainitiative AT kasamakazunori clinicalfeaturesandtreatmentofnonalcoholicfattyliverdiseaseacrosstheasiapacificregionthegoasiainitiative AT kakizakisatoru clinicalfeaturesandtreatmentofnonalcoholicfattyliverdiseaseacrosstheasiapacificregionthegoasiainitiative AT fanjiangao clinicalfeaturesandtreatmentofnonalcoholicfattyliverdiseaseacrosstheasiapacificregionthegoasiainitiative AT songmyeongjun clinicalfeaturesandtreatmentofnonalcoholicfattyliverdiseaseacrosstheasiapacificregionthegoasiainitiative AT yoonseungkew clinicalfeaturesandtreatmentofnonalcoholicfattyliverdiseaseacrosstheasiapacificregionthegoasiainitiative AT danyockyoung clinicalfeaturesandtreatmentofnonalcoholicfattyliverdiseaseacrosstheasiapacificregionthegoasiainitiative AT lesmanalaurentius clinicalfeaturesandtreatmentofnonalcoholicfattyliverdiseaseacrosstheasiapacificregionthegoasiainitiative AT hokhekyu clinicalfeaturesandtreatmentofnonalcoholicfattyliverdiseaseacrosstheasiapacificregionthegoasiainitiative AT gohkheanlee clinicalfeaturesandtreatmentofnonalcoholicfattyliverdiseaseacrosstheasiapacificregionthegoasiainitiative AT wongvincentwaisun clinicalfeaturesandtreatmentofnonalcoholicfattyliverdiseaseacrosstheasiapacificregionthegoasiainitiative |